Now, my team gets to see almost all of the medicines that are in development across the global malaria community because our technology gives researchers a chance to determine their compound’s potential to kill the malaria parasite quickly.
One of the highlights has been my involvement in a group that pioneered GSK’s approach to sharing our data on malaria. We made publicly available the results of GSK screening its entire library of two million compounds against malaria. This exercise indicated whether they could potentially offer a medicine to tackle the disease. Being more open with data is stimulating collaborative research into infectious and neglected diseases, which are notoriously complex areas of research.
Here at Tres Cantos we’ve created an ‘open lab’. We invite external scientists to work alongside GSK scientists on their own projects, focusing on diseases that disproportionately affect developing countries. We’re also involved in collaborations with expert organisations such as the Medicines for Malaria Venture and the Bill and Melinda Gates Foundation.